Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $416 |
| Triangulated Fair Value | $370 |
| 12-mo Scenario PWEV | $411 |
| Implied Return | -11% |
| Forward P/E | 22.2x |
| Market Cap | $369B |
| 52-Week Range | $228 – $418 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Margin Recovery / Re-Rate' (8% weight) — targets $728, +75% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($416) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) — targets $181, -56% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 67% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.30 vs analyst floor +0.16 → delta +0.13 (n=40 mgmt / 17 Q&A; 4th pctile across the S&P book, z -1.6).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.30 | +0.16 | +0.13 |
| 2025Q4 | +0.35 | +0.22 | +0.13 |
| 2025Q3 | +0.33 | +0.13 | +0.20 |
| 2025Q2 | +0.14 | +0.02 | +0.12 |
News (last 365d, 1000 articles): avg ticker sentiment +0.18 (bullish 20% / bearish 2%)
Scenario Analysis
The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($181) to a 'Bull — Margin Recovery / Re-Rate' bull case ($728); the probability-weighted blend (PWEV $411) is -1% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Medicare/Medicaid Reform / MLR Squeeze | 20% | $181 | -56% |
| Cost-Trend Spike / Rate Inadequacy | 17% | $307 | -26% |
| Base — Membership + Premium Growth | 35% | $427 | +3% |
| Growth — MA / Care-Services (Optum-style) | 20% | $576 | +39% |
| Bull — Margin Recovery / Re-Rate | 8% | $728 | +75% |
| Probability-Weighted (PWEV) | — | $411 | -1% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $181). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 181.02; probability: 0.2.
- Cost-Trend Spike / Rate Inadequacy (17%, $307). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 307.4; probability: 0.17.
- Base — Membership + Premium Growth (35%, $427). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 426.94; probability: 0.35.
- Growth — MA / Care-Services (Optum-style) (20%, $576). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 576.37; probability: 0.2.
- Bull — Margin Recovery / Re-Rate (8%, $728). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 727.94; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $362 | -13% |
| Peer P/E re-rate | multiple | $386 | -7% |
| Peer EV/Revenue re-rate | multiple | $1,439 | +246% |
| Scenario PWEV | multiple | $411 | -1% |
| DCF (5-year + terminal) | cash flow + terminal × | $339 | -18% |
| Triangulated (weighted) | — | $370 | -11% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $362 and 41% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (67% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 19x terminal FCF multiple → $339. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 20.64x) implies $386. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Managed Care / Health Services | $449.7B | 100% | 8% | 4% | 22x | 2% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy |
| net_debt_or_cash_b | -49.92 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.02 |
| div_yield | 0.0216 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | Medicare/Medicaid reform / MLR squeeze |
| upside | MA + care-services growth |
Industry Context — Health Payers Providers
This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Cost-Trend Spike / Reimbursement-Reform Squeeze | 37% | 37% | |
| Mid-Cycle — Membership & Volume Growth | 35% | 35% | |
| Upside — Margin Recovery / Care-Services | 28% | 28% |
On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $486B | $23B | $10B | $10B | $17B | $16B |
| FY+2 | $520B | $25B | $10B | $10B | $18B | $16B |
| FY+3 | $551B | $28B | $11B | $10B | $20B | $16B |
| FY+4 | $578B | $29B | $12B | $10B | $21B | $15B |
| FY+5 | $607B | $30B | $12B | $11B | $22B | $14B |
| Terminal | — | — | — | — | $22B × 19x | $274B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $77B + PV(terminal) $274B = EV $351B; + net cash → equity $301B ÷ diluted shares 0.89B = $339/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $308/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 10% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ELV | 0.527x | 14.35x | 8% | 5% |
| HUM | 0.395x | 41.32x | 8% | 5% |
| ABBV | 7.62x | 16.47x | 4% | 32% |
| MRK | 5.37x | 24.81x | 4% | 39% |
| Median | 2.9485x | 20.64x | — | — |
Peer-median fwd P/E → $386; EV/Rev → $1,439.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $339 | 41% | $140 |
| Scenario PWEV | $411 | 29% | $121 |
| Monte Carlo median | $362 | 18% | $64 |
| Peer P/E | $386 | 12% | $45 |
| Triangulated | — | 100% | $370 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 13.3x | 16.1x | 19.0x | 21.8x | 24.7x |
|---|---|---|---|---|---|
| 6% | $272 | $322 | $374 | $424 | $476 |
| 8% | $259 | $307 | $356 | $404 | $453 |
| 8% | $246 | $292 | $339 | $385 | $432 |
| 10% | $234 | $278 | $323 | $366 | $412 |
| 10% | $223 | $265 | $308 | $349 | $392 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $80 | $191 | $301 | $412 | $523 |
| -1.5pp | $83 | $202 | $320 | $438 | $556 |
| +0.0pp | $87 | $213 | $339 | $465 | $591 |
| +1.5pp | $90 | $225 | $359 | $494 | $628 |
| +3.0pp | $94 | $237 | $381 | $524 | $667 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $87 | $591 | $505 |
| Terminal × ±15% | $293 | $385 | $93 |
| Revenue CAGR ±3pp | $301 | $381 | $79 |
| WACC ±1pp | $323 | $356 | $33 |
| FCF conversion ±10% | $339 | $339 | $0 |
Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 22x)
| Multiple | 15.4x | 18.7x | 22.0x | 25.3x | 28.6x |
|---|---|---|---|---|---|
| SoP/share | $7,751 | $9,424 | $11,097 | $12,771 | $14,444 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 19×, FY+5 revenue $607B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $181.
Fact / Inference / Speculation
- FACT: Spot $416; 52-week range $228–$418; engine rating HOLD; base-case target $411 (-1%).
- INFERENCE: Triangulated FV $370 (-11%). Gross Margin explains 67% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 67% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $370 (-11% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (67% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).